Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected
Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off.
Belzutifan, one of the most lucrative assets Merck picked up through its 2019 Peloton buy, s...
Continue Reading →
